22 September 2020
On Friday 18 September, Prime Minister Boris Johnson visited the Old Road Campus Research Building to meet senior researchers from the Medical Sciences Division. The Prime Minister heard about the developments, success and challenges at Oxford in relation to the University’s ongoing COVID-19 research.
2 September 2020
A new arm of the ongoing global clinical trials of the ChAdOx1 nCoV-19 vaccine led by AstraZeneca has launched in the US to assess safety, efficacy and immunogenicity of the vaccine for the prevention of COVID-19.
20 July 2020
The results of the Phase I/II trial published today in the scientific journal, The Lancet, indicate no early safety concerns and induces strong immune responses in both parts of the immune system.
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a Phase I/2 randomized control trial
20 July 2020
The Phase 1 data shows that the vaccine raised no safety concerns, did not lead to any unexpected symptoms in those who received it, and was very similar to other vaccines of this type.
During the COVID-19 pandemic, the Jenner Institute is taking measures to prevent the spread of the disease. Departments are instructed by the University’s Registrar to continue to work from home where possible, and manage the return to on site working, based on the University guidelines for risk assessments and work prioritisation. This is to restrict contact between individuals as far as possible. The University remains open and operating as far as possible with the following restrictions:
- No public access to the University.
- On-site activity permitted where it cannot be undertaken remotely, driven by safety, capacity and other factors such as schools reopening/other changes in government guidelines.
- Teaching and assessment are undertaken remotely where possible and, depending on government guidelines, gatherings of staff and students only permitted where essential for teaching and assessment to take place.
UPDATE ON COVID-19 VACCINE Trial
For all information and enquiries regarding the COVID-19 vaccine trial, please visit: https://covid19vaccinetrial.co.uk/.
Huo J. et al, (2020), Cell Host and Microbe, 28
Campeotto I. et al, (2020), mBio, 11
SUPPORT OXFORD’S COVID-19 VACCINE RESEARCH
Funding for Oxford’s COVID-19 vaccine research requires unprecedented speed, scope and ambition. Support from Government, corporations, trusts and foundations will be crucial to the development of a vaccine to combat the new virus. Alongside those traditional sources of funding, philanthropic donations of any size will have real and rapid impact, allowing us to accelerate this time-critical research, and ensure that Oxford’s vaccine solution will be as effective and swift as possible.
If you are interested in supporting this effort, please make a gift here.